

#### IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re the Application of:	) Group Art Unit:
Bar-Or et al.	Examiner:
Serial No.: 10/679,699	) INFORMATION DISCLOSURE STATEMENT
Filed: October 2, 2003	)
Atty. File No.: 4172-85	CERTIFICATE OF MAILING  I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS
For: "DIAGNOSIS AND MONITORING OF DISEASES"	FIRST CLASS MAIL IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA VA 22313-1450 ON JUNE 8, 2004.  SHBRIDAN ROSS P.C.
Commissioner for Patents	BY Bustana Robout

Dear Sir:

P.O. Box 1450

Alexandria VA 22313-1450

Pursuant to Applicants' duty of disclosure under 37 CFR § 1.56 and 37 CFR §§ 1.97-1.98, Applicants hereby provide a copy of each of the documents identified on the enclosed PTO Form 1449. Applicants do not admit that any of such documents, alone or in any combination, are considered to be material to patentability as defined in 37 CFR § 1.56(b). Moreover, the inclusion of these documents is not to be construed as an admission by Applicants that each such document is prior art as to the above-identified patent application.

Respectfully submitted,

SHERIDAN ROSS P.C.

Gary J. Connell

Registration No. 32,020 1560 Broadway, Suite 1200 Denver, Colorado 80202-5141

(303) 863-9700

Date: Jun 8, 2004

SHEET 1 OF 8

JUN 1 1 2004

**FORM PTO-1449** 

#### PATENT AND THA TMENT OF COMMERCE KADEMARK OFFICE

INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

ATTY. DOCKET NO. 4172-85	SERIAL NO. 10/679,699	
APPLICANT Bar-Or et al.		
FILING DATE October 2, 2003	GROUP ART	

#### **U.S. PATENT DOCUMENTS**

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROP.
	A1.	6,096,737	8/1/2000	Loder	514	217	
	A2.	6,475,743	11/5/2002	Bar-Or et al.	435	7.1	
	A3.	6,555,543	4/29/2003 ·	Bar-Or et al.	514	255.02	
	A4.	6,492,179	12/10/2002	Bar-Or et al.	436	74	
	A5.	6,461,875	10/8/2002	Bar-Or et al.	436	536	
	A6.	6,090,780	7/18/2000	Prasad	514	11	
	A7.	4,771,056	9/13/1988	Rozencwaig	514	325	
	A8.	4,661,500	4/28/1987	Rozencwaig	514	325	

#### FOREIGN PATENT DOCUMENTS

				•		61.15	TRANSLATION	
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB CLASS	YES	NO
	A9.	WO 02/11676	2/14/2002	PCT				
	A10.	NZ 033544	8/31/2001	New Zealand			-	
:	A11.	EP 0 835 660 A1	4/15/1998	EPO				
	A12.	EP 0 214 557 A2	3/18/1987	EPO				
	A13.	EP 0 214 557 A3	3/18/1987	EPO				
	A14.	WO 01/34586	5/17/2001	PCT				
	A15.	WO 00/20454	4/13/2000	PCT				

EXAMINER	DATE CONSIDERED

<b>FORM</b>	<b>PTO</b>	-1449
-------------	------------	-------

### INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

not considered. Include copy of this form with next communication to applicant.

ATTY. DOCKET NO. 4172-85	SERIAL NO. 10/679,699
APPLICANT Bar-Or et al.	
FILING DATE	GROUP ART

						CUD	TRANSL	ATION
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	CLASS		
	A16.	WO 02/059604	8/1/2002	PCT				
•	A17.	WO 00/20840 A1	4/13/2000	PCT				
	A18.	WO 98/40748 A1	9/17/1998	PCT				
	A19.	RU2112242C1	5/27/1998	Russian Federation			X, abstract only	
	A20.	RU2125728C1	1/27/1999	Russian Federation			X, abstract only	
	A21.	RU2128840C1	4/10/1999	Russian Federation			X, abstract only	

#### OTHER ART (Including Author, Title, Date, Pertinent Pages, etc.)

A22.	Esposito et al., "The Solution Structure of the C-Terminal Segment of Tau Protein," Journal of Peptide Science 2000, 6:550-559
A23.	Gamblin et al., "Tau Polymerization: Role of the Amino Terminus," Biochemistry 2003, 42(7):2252-2257
A24.	Crowe et al., "The N Terminal Region of Human Tau is Present in Alzheimer's Disease Protein A68 and is Incorporated into Paired Helical Filaments," <i>American Journal of Pathology</i> 1991, <b>139</b> (6):1463-1470
A25.	Berry et al., "Inhibition of Tau Polymerization by its Carboxy-Terminal Caspase Cleavage Fragment," Biochemistry 2003, 42:8325-8331
A26.	Abraha et al., C-terminal inhibition of tau assembly in vitro and in Alzheimer's disease," Journal of Cell Science 2000, 113:3737-3745
A27.	Bar-Or et al., "An Analog of the Human Albumin N-Terminus (Asp-Ala-His-Lys) Prevents Formation of Copper-Induced Reactive Oxygen Species," <i>Biochemical and Biophysical Research Communications</i> 2001, <b>284</b> (3):856-862

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in confi	ormance with MPEP 600: Draw line through citation if not in conformance and

SHEET	3	OF	Ω

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO. 4172-85	SERIAL NO. 10/679,699	
INFORI	MATION DISCLOSURE STATEMENT (Use several sheets if necessary)	APPLICANT Bar-Or et al.		
		FILING DATE	GROUP ART	

A28.	Bar-Or et al., "Potential Plasma Surrogate Biomarkers for CNS Demyelinating Processes," Meeting of the 19th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Sept. 17-20, 2003 (abstract first distributed at the meeting)
A29.	Garcia-Sierra et al., "Conformational Changes and Truncation of Tau Protein During Tangle Evolution in Alzheimer's Disease," Journal of Alzheimer's Disease 2003, 5:65-77
A30.	Hasegawa et al., "Protein Sequence and Mass Spectrometric Analysis of Tau in the Alzheimer's Disease Brain," Journal of Biological Chemistry 1992, 267(24):17047-17054
A31.	Shutov et al., "[Diagnostic Significance of the type of In Vitro Interaction between Blood Lymphocytes and Serotonin in Multiple Sclerosis]" [Article in Russian], Zh Nevrol Psikhiatr Im S S Korsakova 2002, 102(4):35-38, Abstract only, from PubMed - PMID:12001663
A32.	Lechin et al., "Plasma Neurotransmitters and Cortisol in Chronic Illness: Role of Stress," <i>J Medicine</i> 1994, <b>25</b> (3-4):181-192, <b>Abstract only</b> , from PubMed -PMID:7996062
A33.	Takahara et al., "Detection in Human Serum by Radioimmunoassay of Histidyl-Proline Diketopiperazine, a Metabolite of Thyrotropin-Releasing Hormone," <i>J Clinical Endocrinology</i> 1983, <b>56</b> (2):312-319, <b>Abstract only</b> , from PubMed -PMID:6401750
A34.	Prasad, "Bioactive Cyclic Dipeptides," Peptides 1995, 16:151-164
A35.	Jicha et al., "Sequence Requirements for Formation of Conformational Variants of Tau Similar to Those Found in Alzheimer's Disease," Journal of Neuroscience Research 1999, 55:713-723
A36.	Murray et al., "Role of α-Synuclein Carboxy-Terminus on Fibril Formation in Vitro," <i>Biochemistry</i> 2003, <b>42</b> :8530-8540
A37.	Steiner et al., "Histidyl Proline Diketopiperazine (Cyclo [His-Pro]) in Eating Disorders," Neuropeptides 1989, 14(3):185-189, Abstract only, from PubMed -PMID:2615922
A38.	Prasad et al., "Isolation of cyclo(His-Pro)-like immunoreactivity from Human Urine and Demonstration of its Immunologic, Pharmacologic, and Physico-chemical Identity with the Synthetic Peptide," <i>Biochemistry Int</i> 1990, <b>21</b> (3):425-434, <b>Abstract only</b> , from PubMed -PMID:2222490
A39.	Hilton et al., "Food Contains the Bioactive Peptide, Cyclo(His-Pro), <i>J Clinical Endocrinol Metab</i> 1992, <b>75</b> (2):375-378, <b>Abstract only</b> , from PubMed -PMID:1639938
A40.	Banks et al., "Radioactively Iodinated Cyclo(His-Pro) Crosses the Blood-Brain Barrier and Reverses Ethanol-Induced Narcosis," American J Physiol 1993, <b>264</b> (5 Pt 1):E723-729, <b>Abstract only</b> , from PubMed -PMID:8498494
	· · · · · · · · · · · · · · · · · · ·

EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

<b>FORM</b>	PTO-1	449
-------------	-------	-----

### INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

ATTY. DOCKET NO. 4172-85	SERIAL NO. 10/679,699
APPLICANT Bar-Or et al.	
FILING DATE October 2, 2003	GROUP ART

	A41.	Duntas et al., "A Fast Protein Liquid Chromatography (FPLC) Method for Study of Thyrotropin-releasing Hormone (TRH) and its metabolite Histidyl-Proline Diketopiperazine (CHP) in Human Blood: Degradation in Liver and Pancreatic Diseases," Neuropeptides 1993 25(6):357-361, Abstract only, from PubMed -PMID:8127415
	A42.	Shukla et al., "Role of Endogenous Cyclo(His-Pro) in Cold-Induced Hypothermia in the Desert Rat (Mastomys natalensis)," Peptides 1994, 15(8):1471-1474, Abstract only, from PubMed -PMID:7700849
	A43.	Jaspan et al., "Study of Passage of Peptides Across the Blood-Brain Barrier: Biological Effects of Cyclo(His-Pro) After Intravenous and Oral Administration, <i>Annals of the New York Academy of Science</i> 1994, <b>739</b> :101-107, <b>Abstract only</b> , from PubMed -PMID:7832464
	A44.	Wolf et al., "Identification of Cyclo(His-Pro)-Like Immunoreactivity in Human Follicular Fluid: Correlation with Steroid and Peptide Hormones," <i>J Soc Gynecol Investigation</i> 1994, 1(3):220-224, <b>Abstract only</b> , from PubMed -PMID:9419775
	A45.	Fragner et al., "A New Biological Contribution of Cyclo(His-Pro) to the Peripheral Inhibition of Pancreatic Secretion," <i>American Journal of Physiology</i> 1997, <b>273</b> (6 Pt 1):E1127-32, <b>Abstract only</b> , from PubMed -PMID:9435528
	A46.	Yamada et al., "Abundance of Cyclo (His-Pro)-Like Immunoreactivity in the Brain of TRH-deficient Mice," <i>Endocrinology</i> 1999, 140(1):538-541, Abstract only, from PubMed -PMID:9886867
	A47.	Parker et al., "Evidence for the Presence of Immunoreactive Histidyl-Proline Diketopiperazine [Cyclo (His-Pro)] in the Adult Human Brain," <i>Peptides</i> 1983, 4(6):879-881, <b>Abstract only</b> , from PubMed -PMID:6672793
	A48.	Youngblood et al., "Bovine Serum Albumin-GABA-His-Pro-NH2: an Immunogen for Production of Higher Affinity Antisera for TRH," J Neursci Methods 1983, 9(4):367-373, Abstract only, from PubMed -PMID:6422166
	A49.	Lechan et al., "Thyrotropin Releasing Hormone but not Histidyl-Proline Diketopiperazine is Depleted from Rat Spinal Cord Following 5,7-Dihydroxytryptamine Treatment," <i>Brain Research</i> 1985, <b>326</b> (1):152-155, <b>Abstract only</b> , from PubMed - PMID:3918765
	A50.	Diamanti Kandarakis et al., "Distribution and Characterization of Cyclo (His-Pro)-Like Immunoreactivity in the Human Gastrointestinal Tract," <i>Neuropeptides</i> 1985, 6(1):21-5, Abstract only, from PubMed -PMID:3990923
	A51.	Pekary et al., "In vitro Production of a TRH-Homologous Peptide and His-Pro Diketopiperazine by Human Semen," <i>J Androl</i> 1985, <b>6</b> (6):379-385, <b>Abstract only</b> , from PubMed -PMID:3935636
	A52.	Koskinen, "Effect of Low Intravenous Doses of TRH, Acid-TRH and Cyclo (His-Pro) on Cerebral and Peripheral Blood Flows," British Journal of Pharmacology 1986, 87(3):509-519, Abstract only, from PubMed -PMID:3099875
:	A53.	Prasad et al., "Distribution and Characterization of Cyclo (His-Pro)-Like Immunoreactivity in Human Cerebrospinal Fluid," <i>Biochem Biophys Res Commun</i> 1986, <b>136</b> (2):835-842, <b>Abstract only</b> , from PubMed -PMID:2871837
		· · · · · · · · · · · · · · · · · · ·

EXAMINER	DATE CONSIDERED
*FVANIAIFD Living 16 of the control	WARED COOP II

## INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

ATTY. DOCKET NO. 4172-85	SERIAL NO. 10/679,699
APPLICANT Bar-Or et al.	
FILING DATE October 2, 2003	GROUP ART

Kurahashi et al., ["Histidyl-Proline Diketopiperazine (HPD) a Metabolite of Thyrotripin-Releasing Hormone (TRH), Improves the Ataxic Gait in 3-Acetylpyridine (3-AP) Treated Rats"] [Article in Japanese] No To Shineki 1986, 38(9):893-898, Abstract only, from PubMed -PMID:3790371
Coggins et al., "High Affinity Specific Binding of the Thyrotrophin Releasing Hormone Metabolite Histidylproline to Rat Brain Membranes," Neuropeptides 1987, 9(1):83-91, Abstract only, from PubMed -PMID:3104816
Mori et al., "Specific Radioimmunoassay of Cyclo (His-Pro), a Biologically Active Metabolite of Thyrotropin-Releasing Hormone," Endocrinology 1981, 108(5):1995-1997, Abstract only, from PubMed -PMID:6783397
Mori et al., "Regional Dissociation of Histidyl-Proline Diketopiperazine (Cyclo-(His–Pro)) and Thyrotropin-Releasing Hormone (TRH) in the Rat Brain," <i>Brain Research</i> 1982, <b>231</b> (2):451-453, <b>Abstract only</b> , from PubMed -PMID:6799149
Prasad et al., "Distribution and Metabolism of Cyclo (His-Pro): a New Member of the Neuropeptide Family," <i>Peptides</i> 1982, 3(3):591-598, <b>Abstract only</b> , from PubMed -PMID:6812031
Mori et al., "Histidyl-Proline Diketopiperazine Cyclo (His-Pro): Identification and Characterization in Rat Pancreatic Islets," Biochem Biophys Res Commun 1983, 115(1):281-286, Abstract only, from PubMed -PMID:6351862
Mitsuma et al., "Radioimmunoassay for Thyrotropin-Releasing Hormone Precursor Peptide, Lys-Arg-Gln-His-Pro-Gly-Arg-Arg," Exp Clin Endocrinology 1989, 93(1):53-60, Abstract only, from PubMed -PMID:2500352
Gu et al., "Diketopiperazine Formation, Hydrolysis, and Epimerization of the New Dipeptide Angiotensin-Converting Enzyme Inhibitor RS-10085," <i>Pharm Res</i> 1987, <b>4</b> (5):392-397, <b>Abstract only</b> , from PubMed -PMID:3508548
Guerra et al., "PEGylation Prevents the N-Terminal Degradation of Megakaryocyte Growth and Development Factor," Pharm Res 1998, 15(12):1822-1827, Abstract only, from PubMed -PMID:9892464
Sepetov et al., "Rearrangement, Racemization and Decomposition of Peptides in Aqueous Solution," <i>Peptide Research</i> 1991, 4(5):308-313, <b>Abstract only</b> , from PubMed -PMID:1802242
Reubsaet et al., "Qualitative and Quantitative Aspects of the Degradation of Several Tripeptides Derived from the Antitumor Peptide Antagonist [Arg(6), D-Trp(7,9), MePhe(8)] Substance P[6-11]," <i>J Pharm Biomed Anal</i> 1999, 19(3-4):277-284, Abstract only, from PubMed -PMID:10704092
Song et al., "Synergistic Antidiabetic Activities of Zinc, Cyclo (His-Pro), and Arachidonic Acid," <i>Metabolism</i> 2001 <b>50</b> (1):53-59, <b>Abstract only</b> , from PubMed -PMID:11172475
Rosenthal et al., "Effects of Arachidonic Acid and Cyclo (His-Pro) on Zinc Transport Across Small Intestine and Muscle Tissues,"

EXAMINER	DATE CONSIDERED	
*EVAMINED: Initial if reference considered substhess or not citation is in conference with MDED 600; Draw line through citation if not in conference and		

<b>FORM</b>	PTO-1449
1 01 (14)	1 10 1770

### INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

ATTY. DOCKET NO. 4172-85	SERIAL NO. 10/679,699
APPLICANT Bar-Or et al.	
FILING DATE October 2, 2003	GROUP ART

A67.	Pandey et al., "Synthetic Peptides Corresponding to a Repetitive Sequence of Malarial Histidine Rich Protein Bind Haem and Inhibit Haemozoin Formation in vitro," <i>Mol Biochem Parasitol</i> 1997, <b>90</b> (1):281-287, <b>Abstract only</b> , from PubMed -PMID:9497049
A68.	Baig et al., "High Performance Liquid Chromatography as a Tool in the Definition of Abnormalities in Monamine and Tryptophan Metabolites in Cerebrospinal Fluid from Patients with Neurological Disorders," <i>Biomed Chromatogr</i> 1991, 5(3):108-112, <b>Abstract only</b> , from PubMed -PMID:1863084
A69.	Monaco et al., "Plasma and cerebrospinal fluid tryptophan in Multiple Sclerosis and Degenerative Diseases," <i>J Neurol Neurosurg Psychiatry</i> 1979 <b>42</b> (7):640-1, <b>Abstract only</b> , from PubMed -PMID:479903
A70.	Scharpe et al., "Peptide Truncation by Dipeptidyl Peptidase IV: A New Pathway for Drug Discovery," Verh K. Acad Geneeskd Belg. 2001, 63(1):5-32, Abstract only, from PubMed -PMID:11284388
A71.	Mentlein et al., "Dipeptidyl-Peptidase IV Hydrolyses Gastric Inhibitory Polypeptide, Glucagon-Like Peptide-1(7-36)amide, Peptide Histidine Methionine and is Responsible for their Degradation in Human Serum," European Journal of Biochemistry 1993, 214(3):829-835, Abstract only, from PubMed -PMID:8100523
A72.	Hilton et al., "Radioimmunoassay of Cyclo(His-Pro) in Unextracted Human Plasma: Report of a Normal Range and Definition of Factors Critical for Successful Assay," <i>Neuropeptides</i> 1989, 13(1):65-70, Abstract only, from PubMed -PMID:2922107
A73.	Iriuchijima et al., "Thyrotripin-Releasing Hormone and Cyclo (His-Pro)-Like Immunoreactivities in the Cerebrospinal Fluids of Normal' Infants and Adults, and Patients with Various Neuropsychiatric and Neurologic Disorders," <i>Life Sci.</i> 1987, 41(22):2419-2428, Abstract only, from PubMed -PMID:2891013
A74.	Hilton et al., "Relationship between Plasma Cyclo (His-Pro), a Neuropeptide Common to Processed Protein-Rich Food, C-Peptide/Insulin Molar Ratio in Obese Women," <i>Nutr Neurosci</i> 2001, <b>4</b> (6):469-474, <b>Abstract only</b> , from PubMed -PMID:11843266
A75.	Mori et al., "Brain TRH and Cyclo (His-Pro) and Brain Protein in the Newborn Rat are Altered by Maternal Liquid Protein Feeding," Life Sci 1983, 32(14):1607-1612, Abstract only, from PubMed -PMID:6403790
A76.	Mori et al., ["TRH and Cyclo (His-Pro) Concentrations in the Young Rat Brain are Altered by a Liquid Protein Diet]" [Article in Japanese], Nippon Naibunpi Gakkai Zasshi 1987, 63(7):846-852
A77.	Mori et al., "Alteration by Liquid Protein Diet of TRH and Cyclo(His-Pro) in the Young Rat Brain," Res. Commun Chem Pathol Pharmacol 1985, 47(1):157-160, Abstract only, from PubMed -PMID:392073
A78.	Goolcharran et al., "Comparison of the Rates of Deamidation, Diketopiperazine Formation and Oxidation in Recombinant Human Vascular Endothelial Growth Factor and Model Peptides," <i>AAPS PharmSci</i> 2000, <b>2</b> (1)E5, <b>Abstract only</b> , from PubMed - PMID:11741221

EXAMINER	DATE CONSIDERED
*EVANINED: Initial if reference considered whether or not sitetion is in early	AMPER COOL Provides through situation if not in conformation and

FORM PTO-1449

# U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

### INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

ATTY. DOCKET NO. 4172-85	SERIAL NO. 10/679,699
APPLICANT Bar-Or et al.	
FILING DATE October 2, 2003	GROUP ART

,	A79.	Moss et al., "Kinetics and Mechanism of the Facile Cyclization of Histidyl-Prolineamide to Cyclo (His-Pro) in Aqueous Solution and the Competitive Influence of Human Plasma," <i>J Pharm Pharmacol</i> 1990, <b>42</b> (1):7-12, <b>Abstract only</b> , from PubMed - PMID:1969958
,	A80.	Hilton et al., "Identification and Characterization of Cyclo (His-Pro)-Like Immunoreactivity in Amniotic Fluid," <i>Peptides</i> <b>10</b> (2):299-301, <b>Abstract only</b> , from PubMed -PMID:2755872
,	A81.	Bhargava et al., "Inhibition of Neuroleptic-Induced Dopamine Receptor Supersensitivity by Cyclo (Leu-Gly)," <i>Pharmacol Biochem Behav</i> 1980, <b>13</b> (5):633-636, <b>Abstract only</b> , from PubMed -PMID:7443732
,	A82.	Leduque et al., "Histidyl-Proline Diketopiperazine (His-Pro DKP) Immunoreactivity is Present in the Glucagon-Containing Cells of the Human Fetal Pancreas," <i>J Clin Invest</i> 1987, <b>79</b> (3):875-880, <b>Abstract only</b> , from PubMed -PMID:3102558
,	A83.	Battersby et al., "Diketopiperazine Formation and N-Terminal Degradation in Recombinant Human Growth Hormone," Int J Peptide Protein Res 1994, 44(3):215-222, Abstract only, from PubMed -PMID:7822097
,	A84.	Bhargava et al., "Inhibition of Neuroleptic-Induced Dopamine Receptor Supersensitivity by Cyclo (Leu-Gly)," <i>Pharmacol. Biochem Behav</i> 1980, <b>13</b> (5):633-636, <b>Abstract only</b> , from PubMed -PMID:7443732
,	A85.	Yanagisawa et al., "The Subcellular and Organ Distribution and Natural Form of Histidyl-Proline Diketopiperazine in Rat brain Determined by a Specific Radioimmunoassay," <i>J Biol Chem</i> 1980, <b>255</b> (21):10290-10294, <b>Abstract only</b> , from PubMed - PMID:7430126
,	A86.	Hoffman et al., "An Enzymatically Stable Peptide with Activity in the Central Nervous System: Its Penetration Through to Blood-CSF Barrier," Brain Res. 1977, 122(1):87-94, Abstract only, from PubMed -PMID:837226
A	A87.	Meester et al., "In Vivo Inhibition of Dipeptidyl Peptidase IV Activity by Pro-Pro-diphenyl-phosphonate (Prodipine)", Biochemical Pharmacology 1997, 54:173-179
4	A88.	Prasad et al., "Thermoregulation in rats: opposing effects of thyrotropin releasing hormone and its metabolite histidyl-proline diketopiperazine," Biochem Biophys Res. Commun. 1978, 85(4):1582-187
F	A89.	Wilber et al., "Histidyl-proline diketopiperazine: a potent and chronic appetite-inhibiting neuropeptide," <i>Trans Assoc. Am Physicians</i> 1986, <b>99</b> :245-249
P	A90.	Wilber et al., "Endogenous histidyl-proline diketopiperazine [cyclo (His-Pro)]: a potential satiety neuropeptide in normal and genetically obese rodents," <i>Trans Assoc Am Physicians</i> 1983, <b>96</b> :131-136
1	A91.	Bhargava, "Inhibition of abstinence syndrome in opiate dependent mice by cyclo (His-Pro), Life Sci 1981, 28(11):1261-1267
A	A92.	Bhargava, "The effects of thyrotropin releasing hormone and histidyl-proline diketopiperazine on delta-9-tetrahydrocannabinol-induced hypothermia," Life Sci 1980, 26(11):845-850
<del></del>		

EXAMINER	DATE CONSIDERED	
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

SHEET	۰	$\triangle$ E	0
SHEEL	O	U.E	Ω.

**FORM PTO-1449** 

#### U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

## INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)

ATTY. DOCKET NO. 4172-85	SERIAL NO. 10/679,699
APPLICANT Bar-Or et al.	
FILING DATE October 2, 2003	GROUP ART

A93.	Bhargava, "Antagonism of ketamine-induced anesthesia and hypothermia by thyrotropin releasing hormone and cyclo (His-Pro)," Neuropharmacology 1981, <b>20</b> (7):699-702
A94.	Mori et al., "Histidyl-Proline Diketopiperazine cyclo (His-Pro): measurement by radioimmunoassay in human blood in normal subject and in patients with hyper- and hypothyroidism," <i>Biochem Biophys Res Commun</i> 1982, <b>109</b> (2):541-547
 A95.	Luca et al., "Determination of serotonin content and ceruloplasmin activity, of blood and CSF amino acid level in multiple sclerosis," Neurol Psychiatr (Bucur) 1986, 24(3):153-159
A96.	Mori et al., "Distribution of histidyl-proline diketopiperazine [cyclo (His-Pro)] and thyrotropin-releasing hormone (TRH) in the primate central nervous system," <i>Brain Res</i> 1982, <b>245</b> (1):183-186

EXAMINER DATE CONSIDERED